Chandra Vage

Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice

Yan Weng, J Chabot, Barbara Bernardo et al. · PLoS ONE · 2015 · 67 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation

Amit S. Kalgutkar, Deepak Dalvie, Jiri Aubrecht et al. · Drug Metabolism and Disposition · 2007 · 53 citations

Pharmacy, Pharmacology, Toxicology +14

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

Mary E. Spilker, Xiaoying Chen, Ravi Visswanathan et al. · Clinical Cancer Research · 2016 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretion<i>ex vivo</i>

Jimmy Kong, J Chuddy, Ingrid A. Stock et al. · British Journal of Pharmacology · 2016 · 27 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity

Kevin K.‐C. Liu, Peter Cornelius, Terrell A. Patterson et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 22 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10